newsfilter
← Latest News
ACCESS Newswire·

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings create runway